Literature DB >> 12508142

Herpes simplex virus type 2 infection as a risk factor for human immunodeficiency virus acquisition in men who have sex with men.

Cristina Renzi1, John M Douglas, Mark Foster, Cathy W Critchlow, Rhoda Ashley-Morrow, Susan P Buchbinder, Beryl A Koblin, David J McKirnan, Kenneth H Mayer, Connie L Celum.   

Abstract

The association of human immunodeficiency virus (HIV) acquisition with herpes simplex virus type 2 (HSV-2) was assessed among men who have sex with men (MSM) in a nested case-control study of 116 case subjects who seroconverted to HIV during follow-up and 342 control subjects who remained HIV seronegative, frequency-matched by follow-up duration and report of HIV-infected sex partner and unprotected anal sex. The baseline HSV-2 seroprevalence was higher among case (46%) than control (34%) subjects (P=.03); the HSV-2 seroincidence was 7% versus 4% (P=.3). Only 15% of HSV-2-infected MSM reported herpes outbreaks in the past year. HIV acquisition was associated with prior HSV-2 infection (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.1-2.9), reporting >12 sex partners (OR, 2.9; 95% CI, 1.4-6.3), and reporting fewer herpes outbreaks in the past year (OR, 0.3; 95% CI, 0.1-0.8). HSV-2 increases the risk of HIV acquisition, independent of recognized herpes lesions and behaviors reflecting potential HIV exposure. HSV-2 suppression with antiviral therapy should be evaluated as an HIV prevention strategy among MSM.

Entities:  

Mesh:

Year:  2003        PMID: 12508142     DOI: 10.1086/345867

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Performance and use of a ribonucleotide reductase herpes simplex virus type-specific serological assay.

Authors:  S Q Wales; C C Smith; M Wachsman; G Calton; L Aurelian
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

2.  Efforts to Control Sexually Transmitted Infections As a Means to Limit HIV Transmission: What Is the Evidence?

Authors:  Gina Dallabetta; Graham Neilsen
Journal:  Curr Infect Dis Rep       Date:  2005-01       Impact factor: 3.725

Review 3.  Efforts to control sexually transmitted infections as a means to limit HIV transmission: what is the evidence?

Authors:  Gina Dallabetta; Graham Neilson
Journal:  Curr HIV/AIDS Rep       Date:  2004-12       Impact factor: 5.071

4.  Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.

Authors:  Sita Awasthi; John M Lubinski; Carolyn E Shaw; Shana M Barrett; Michael Cai; Fushan Wang; Michael Betts; Susan Kingsley; Daniel J Distefano; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

5.  A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.

Authors:  Sita Awasthi; Gregory G Mahairas; Carolyn E Shaw; Meei-Li Huang; David M Koelle; Christine Posavad; Lawrence Corey; Harvey M Friedman
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

6.  Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study).

Authors:  Ruanne V Barnabas; Judith N Wasserheit; Yunda Huang; Holly Janes; Rhoda Morrow; Jonathan Fuchs; Karen E Mark; Martin Casapia; Devan V Mehrotra; Susan P Buchbinder; Lawrence Corey
Journal:  J Acquir Immune Defic Syndr       Date:  2011-07-01       Impact factor: 3.731

7.  An intravaginal ring for the simultaneous delivery of multiple drugs.

Authors:  Marc M Baum; Irina Butkyavichene; Joshua Gilman; Sean Kennedy; Etana Kopin; Amanda M Malone; Cali Nguyen; Thomas J Smith; David R Friend; Meredith R Clark; John A Moss
Journal:  J Pharm Sci       Date:  2012-05-22       Impact factor: 3.534

8.  Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding.

Authors:  Joshua T Schiffer; Bryan T Mayer; Youyi Fong; David A Swan; Anna Wald
Journal:  J R Soc Interface       Date:  2014-03-26       Impact factor: 4.118

9.  Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.

Authors:  Sita Awasthi; John W Balliet; Jessica A Flynn; John M Lubinski; Carolyn E Shaw; Daniel J DiStefano; Michael Cai; Martha Brown; Judith F Smith; Rose Kowalski; Ryan Swoyer; Jennifer Galli; Victoria Copeland; Sandra Rios; Robert C Davidson; Maya Salnikova; Susan Kingsley; Janine Bryan; Danilo R Casimiro; Harvey M Friedman
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

10.  Seroprevalence and factors associated with herpes simplex virus type 2 among HIV-negative high-risk men who have sex with men from Rio de Janeiro, Brazil: a cross-sectional study.

Authors:  Junia Rodrigues; Beatriz Grinsztejn; Francisco I Bastos; Luciane Velasque; Paula M Luz; Claudia T V de Souza; Ingebourg Georg; Jose H Pilotto; Valdilea G Veloso
Journal:  BMC Infect Dis       Date:  2009-04-01       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.